Podcast appearances and mentions of Peter Goodwin

Ever had one of those moments where you step back from everything you have built and ask yourself a simple but uncomfortable question. What is all this actually for? Many entrepreneurs chase success with relentless energy. Bigger revenue. Bigger teams. Bigger assets. Bigger everything. But eventually a deeper question surfaces. If you already have enough, what keeps you going? In this episode of The Happy Hustle Podcast, I sit down with entrepreneur and outdoorsman Peter Goodwin for a raw and honest conversation about success, identity, and building a life that actually means something. Peter shares his journey from a rugged bush guide with no college degree to building a thriving business and raising a family he deeply loves. Along the way, he opens up about insecurity, purpose, and the surprising lessons that come when you realize money alone is not the destination. Peter is an entrepreneur, lodge owner, and passionate outdoorsman who built his career through grit, problem-solving, and relentless determination. Without a traditional path or backup plan, he learned how to navigate uncertainty and create opportunity from nothing. His story is a powerful reminder that resourcefulness, resilience, and purpose often matter far more than credentials. Through his work, Peter has built businesses, supported communities, and most importantly, created a life centered around family and meaningful impact. This episode matters because it speaks directly to the quiet struggles many entrepreneurs face. The self-doubt. The pressure to prove yourself. The temptation to measure success purely by money or status. Peter's story shows that real success comes when your work supports your life rather than consuming it. Peter shares that some of his darkest moments came while building his lodge. At the time, he had no formal training in business, so he literally Googled his way through creating a business plan and learning how to use PowerPoint. He pitched to anyone who would listen and faced constant rejection. During that time, the inner voice of doubt was loud. Am I enough? Do I have what it takes? Should I have gone to college? Those thoughts can hit especially hard when you are surrounded by people who seem more accomplished on paper. Yet those moments of doubt also forced him to grow into the man he needed to become. Another powerful lesson Peter shares is the idea that having no backup plan can actually be a gift. When you grow up solving problems with limited resources, you become incredibly resourceful. Living in remote environments taught him that when something breaks, you cannot just run somewhere else to fix it. You have to figure it out. That mindset carried over into business and became one of his greatest advantages. Peter also offers a refreshing perspective on identity. He believes that a huge portion of life is simply figuring out who you are not. Many people spend years trying to imitate mentors, parents, or people they see online. But constantly trying to be someone else creates pressure and frustration. Real freedom comes when you stop chasing those comparisons and become comfortable with who you truly are. Perhaps the most striking moment in the conversation comes when Peter talks about reaching financial success. At one point, he had more assets than he ever imagined. Boats, planes, land, tractors, and everything that many people dream of owning. But instead of feeling fulfilled, he realized he could not even keep up with maintaining it all. That moment forced him to ask a deeper question. Why am I working this hard if my family is already provided for? That realization sparked a shift. Success stopped being about accumulation and started being about purpose. Peter realized he needed something bigger than money driving him forward. Something meaningful. Something aligned with the life he wanted to live. This conversation with Peter Goodwin is a powerful reminder that entrepreneurship is not just about building a business. It is about building a life. One where your work supports your values, your purpose, and the people who matter most. If you are navigating your own entrepreneurial journey and searching for clarity around success, identity, and purpose, this episode will resonate deeply. Listen to the full conversation now at caryjack.com/podcastin and keep Happy Hustlin'. What does Happy Hustlin mean to you? Peter says Happy hustlin' is putting my family first, and then also winning at any, whatever game you're in, like winning and that balance it, you know, the family keeps you, that's what keeps me grounded. Cause I can kind of work and just completely bury myself in the game. Love the game, but when you go back home, and you're like, this is what it's all about. So enjoy the game. But don't burn out on the game. The game is just, it's just part of life. It's not life for sure. Connect with Peterhttps://www.instagram.com/groovelife/https://www.facebook.com/groovelife.cohttps://www.linkedin.com/in/petergoodwinak/https://www.youtube.com/channel/UCJmCr41eOvPY4LjG3MQeGUA Find Peter on his website: https://www.groovelife.com/ Connect with Cary!https://www.instagram.com/caryjack/https://www.facebook.com/SirCaryJackhttps://www.linkedin.com/in/cary-jack-kendzior/https://twitter.com/thehappyhustlehttps://www.youtube.com/channel/UCFDNsD59tLxv2JfEuSsNMOQ/featured Get a copy of his new book, https://www.thehappyhustle.com/book Sign up for The Journey: 10 Days To Become a Happy Hustler Online Course @ https://thehappyhustle.com/thejourney/ Apply to the Montana Mastermind Epic Camping Adventure @ https://thehappyhustle.com/mastermind/ “It's time to Happy Hustle, a blissfully balanced life you love, full of passion, purpose, and positive impact!” Episode Sponsors: If you're feeling stressed, not sleeping great, or your energy's been kinda meh lately—let me put you on to something that's been a total game-changer for me: Magnesium Breakthrough by BiOptimizers. This ain't your average magnesium—it's got all 7 essential forms that your body needs to chill out, sleep deeper, and feel more balanced. I take it every night and legit notice the difference the next day. No more waking up groggy or tossing and turning all night If you're ready to sleep like a baby, calm your nervous system, and optimize your recovery, go grab yours now at bioptimizers.com/happy and use code HAPPY10 for 10% OFF.

What if the greatest gift you could give your son isn't a car, a college fund, or a successful life—but a deep sense that he is beloved?In this episode, Jerrad sits down with Peter Goodwin and Connor Ketchum from The Quarry Project, a father–son camp in Alaska helping dads disciple their boys into biblical manhood. Together, they unpack what it really means to raise sons who know who they are, where they come from, and what they're made for.Through honest stories, theological insight, and real-world examples, they explore how today's dads can break generational cycles and become the kind of fathers who bless rather than wound.With a mix of vulnerability and hope, this episode will help you:Understand the power of a father's blessingLearn why “beloved sonship” is the foundation of manhoodRecognize how your own father wounds impact your parentingDiscover what true initiation into manhood looks likeSee how God can redeem your family's story through youWhether you had a great dad or no dad at all, this episode is a powerful reminder that strong families begin with healed men—and your son's journey into manhood starts with you.Prayer:“Father, help me see my son the way You see me—beloved, chosen, and full of purpose.”Scriptures MentionedIsaiah 51:1–2Luke 3:21–22Ephesians 1:5–6Proverbs 22:6Deuteronomy 6:6–7Resources & LinksToday's Sponsor: The One Year Bible by TyndaleRegister for the Dad Tired x Quarry Project Father–Son Trip → thequarryproject.comInvite Jerrad to Speak at Your ChurchBecome a Monthly Partner

About Peter GoodwinPeter Goodwin is a British entrepreneur and longtime UAE resident whose career began in the fine art industry and evolved into building ventures that help others launch theirs. After two decades working with founders—and founding companies himself—Peter created idea-L (Idea-Live), a “co-founder in your pocket” that blends AI guidance with human support to help anyone, anywhere, take an idea from spark to launch.A believer that entrepreneurs are made (not born), Peter champions bravery, bias-to-action, and originality. He once cycled 9,000 km from the UK to Rwanda in 66 days to raise funds for sport in schools—an experience that sharpened his views on resilience, teamwork, and the goodness of people.About this EpisodeIn this energizing conversation, Peter shares how a spontaneous “yes” to a charity ride became a life-shaping lesson in momentum—keep moving, choose your team wisely, and trust that most people want to help. He then dives into idea-L, a platform built from his frustration with how hard starting up can be and his conviction that anyone can be an entrepreneur with the right scaffolding.Peter explains idea-L's vision of a supportive, always-on co-founder that fills skill gaps, reduces isolation, and nudges daily progress. He introduces the PREVENT Matrix—seven common blockers the platform tackles: Psychology, Resources, Expertise, Vision, Execution, Network, and Timing. Beyond AI, idea-L keeps humans in the loop through a “team live” execution service and upcoming mentor matching, while its funding model uses Web3 to agentically deploy capital based on proof-of-work, not pitch theater.You'll also hear Peter's practical playbook for founders: don't rely on motivation—start anyway; “eat the frog” early; design your environment to help you win; and reframe “setbacks” as part of the path. His core advice: be brave, trust your instincts, and go where others aren't.Quotes1:01 - My journey fundamentally has been in the fine art industry. 2:02 - I think in life everything that's happened to me has been quite spontaneous. So, I tend not to plan too far ahead. 4:33 - I think fundamentally that one of the secrets to doing anything is to say yes and then work it out. 5:36 - Don't give up is definitely one of them. And keep moving. Choose your team wisely. 5:47 - I've got to say that the one lesson that really stood out was the people I met on the road, and when you're on a bike, right, a bicycle, you're exposed to everything, everyone, all the time. If you're not a social person, you need to become one. 6:12 - I just really found out all people are the same. People are inherently good. They inherently want to help you If you ask for help. 9:27 - If you have an excellent co-founder, your chance of success is 10x what it should be. 10:51 - I have a personal very strong dislike for kind of discrimination, right to whatever degree, and when I say that what I mean is the mantra that entrepreneurs are born, not made. 11:57 - The most successful artists are the ones who work the hardest, who make the most mistakes and brave enough to put themselves out there and do things with sincerity. And it's the same being an entrepreneur, because to be an entrepreneur is to be creative. You have to be inherently creative and everyone is born creative. 12:19 -I believe every child is an entrepreneur. It's just difficult to remain an entrepreneur as you go through education and then you start to get boxed in certain areas and told you have to choose a career and stay in one thing. 17:59 - We encourage people notThe Matrix Green Pill Podcast: https://thematrixgreenpill.com/Please review us: https://g.page/r/CS8IW35GvlraEAI/review

Peter Goodwin is the CEO and founder of Idea-L®, the platform that combines generative AI and real-time validation to help anyone go from idea to funded startup, without gatekeepers. Think: “AI x AngelList meets Product Hunt — but fully decentralized.” Why you should listen idea‑L® is an AI-powered, Web3-native platform designed to accelerate the journey from concept to launch. At its heart is a step-by-step process—Imagine, Design, Execute, Accelerate, and Live—providing founders with a structured framework to turn bold ideas into viable ventures without the usual guesswork. This fusion of AI-driven validation, decentralized funding via the GovToken, and human mentorship redefines early-stage entrepreneurship by making it accessible, intuitive, and speed-focused. Beyond automation, idea‑L® embeds Web3-powered transparency and community governance into its DNA. Its tech stack includes predictive analytics, smart contracts, and a DAO-based decision-making structure—all delivered through an agile, intuitive interface. Token holders gain real voting power, staking benefits, and fee-based perks, while the platform steers clear of insider privilege—no presales, and no secret taps to exclusivity. Currently in private beta ahead of a 2025 GovToken public launch, idea‑L® is based in Dubai but operates globally, targeting founders of any background or mission type—commercial, social, or public good. It's positioning itself as a democratic co‑founder: always on, structured, and deeply rooted in fairness and momentum. If you're tired of the startup snail's pace and gatekept funding, idea‑L® is staking its claim as the launchpad that tells it like it is. Supporting links Stabull Finance Idea-L®  Andy on Twitter  Brave New Coin on Twitter Brave New Coin If you enjoyed the show please subscribe to the Crypto Conversation and give us a 5-star rating and a positive review in whatever podcast app you are using.  

For episode 527, Brandon Zemp is joined by Peter Goodwin CEO & founder of idea-L, an AI and Web3 platform equipping entrepreneurs with the resources to transform any business idea into a reality.Using AI-powered technology, the platform allows entrepreneurs to assess the viability of an idea early in the ideation process, enabling them to make data-driven decisions on if, and how to move forward before investing significant time, capital, and resources.⏳ Timestamps: 0:00 | Introduction1:04 | Who is Peter Goodwin?2:40 | UAE hub for AI3:47 | What is idea-L?8:18 | Why Entrepreneurs struggle12:15 | What is the process behind idea-L?17:12 | IRP, IFP & DeVC Fund20:52 | Criteria to apply24:48 | Capital funding caps27:17 | VC ecosystem today33:26 | idea-L roadmap 

Burning Topic for Pediatric Physical Therapists: In the USA and Globally Pediatric Physical Therapy Editor-in-Chief Linda Fetters PhD, PT, FAPTA, gives reporter Peter Goodwin her assessment of the organizational crisis that has enveloped pediatric and other clinicians in the USA and globally since the new Administration took office in 2025.Predictors of Length of Physical Therapy Care for Infants With Congenital Torticollis. We talk with Pediatric Physical Therapy author Heather R Aker PT DHSc, Physical Therapist, at the Children's Hospital, Philadelphia, about her research findings published in Pediatric Physical Therapy on: Predictors of Length of Physical Therapy Care for Infants with Congenital Torticollis. Pediatric Physical Therapy Editor-in-Chief Linda Fetters adds her comments.PLEASE JOIN THE CONVERSATION!! We need to know your views, and we would love you to take part in the podcast. Please send us your perspectives and interpretations of the issues you would like us to air on the podcast. You can contact us at: E-mail: pediatricphysicaltherapy@audiomedica.comText Messages, WhatsApp, What's App Video or Audio: +44 7771 642 333

A tumor-agnostic classifier and screening tool was announced at ESMO Congress 2024 in Barcelona. It was created to make it easier and quicker to develop new drugs that have specific molecular targets, and thus have potential anti-cancer efficacy irrespective of tumor type or location. The ESMO Tumour-Agnostic Classifier and Screener was the result of work by a multidisciplinary team of international experts led by the ESMO Precision Medicine Working Group. At the conference, Benedikt Westphalen, MD, a medical oncologist and molecular biologist who is Head of the Precision Oncology Program at the University of Munich in Germany, talked about the details with Oncology Times correspondent Peter Goodwin.

In a Phase I study with 318 patients in China and Australia the antibody-drug conjugate (ADC) IBI354 was found to be safe and have promising efficacy in patients whose breast and other solid tumors tested positive for HER2 or were categorized as “HER2-low.” At ESMO Congress 2024, the study also reported a low rate of interstitial lung disease in patients treated with the ADC. Oncology Times correspondent Peter Goodwin talked with Christina Teng, PhD, the presenting author of the new research from Scientia Clinical Research and the Prince of Wales Hospital in Sydney, Australia.

Patients with muscle-invasive bladder cancer experienced “clinically meaningful” improvements in key outcomes—event-free survival and overall survival—when the immune checkpoint inhibitor durvalumab was added to their standard neoadjuvant chemotherapy. This was in research findings, reported at the ESMO Congress 2024, from the NIAGARA randomized Phase Ill trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in patients with cisplatin-eligible muscle-invasive bladder cancer. After his talk at the ESMO Barcelona conference, first author Thomas Powles, MBBS, MRCP, MD, from the Barts Cancer Institute at Queen Mary University of London, UK, met up with Oncology Times correspondent Peter Goodwin.

Sustained responses and long-term overall survival have resulted from checkpoint inhibitor therapy for advanced melanoma, transforming the prognosis for as many as half of patients. This is according to 10-year survival outcomes from the Phase Ill CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma that were reported at the ESMO Congress 2024. At the conference, Oncology Times reporter, Peter Goodwin, caught up with James Larkin, FRCP, PhD, Professor and Medical Oncologist at the Royal Marsden Hospital in London.

The addition of preoperative chemoradiation therapy to perioperative chemotherapy did not improve overall survival as compared with perioperative chemotherapy alone in patients with resectable gastric or gastroesophageal junction adenocarcinomas. The multi-continent, Phase III randomized TOPGEAR trial has definitively found no benefit from adding radiation before surgery in terms of overall or progression-free survival. This clear finding was reported simultaneously in the New England Journal of Medicine and at the ESMO 2024 Congress held in Barcelona, Spain. After presenting the findings , first author Trevor Leong, MD, Radiation Oncologist at the Peter McCallum Cancer Centre in Melbourne, Australia, met up with Oncology Times reporter Peter Goodwin.

When patients with recurrent high-grade glioblastoma were treated with autologous myeloid dendritic cells, they had clinical responses described as “encouraging” in a Phase I clinical trial reported at the ESMO Congress 2024. Cells harvested from each patient were injected directly into the resection cavity brain tissue lining after surgery. Patients also received intracranial injections of the checkpoint inhibitor combination: nivolumab + ipilimumab. At the conference, Oncology Times reporter Peter Goodwin caught up with lead author of the study, Bart Neyns, MD, PhD, Head of Medical Oncology at the Vrije Universiteit Brussel in the University Hospital Brussels Faculty of Medicine & Pharmacy in Belgium.

Patients with newly diagnosed, surgically resected MGMT-unmethylated glioblastoma may benefit from treatment with a therapeutic mRNA vaccine called CVGBM, according to findings from a first-in-human, Phase I safety and dose-escalation study from Tübingen, Germany, reported at the ESMO Congress 2024 held in Barcelona. The CVGBM vaccine encodes multiple molecular features derived from tumor-associated antigens, all of which were judged to be potentially relevant in glioblastoma. After reporting her group’s findings to the ESMO Barcelona meeting, first author Ghazaleh Tabatabai, MD, PhD, a neurologist, Professor of Neuro-Oncology, and Chair of the Department of Neurology and Interdisciplinary Neuro-Oncology at the University Hospital, Tübingen, Germany, talked about the findings with Oncology Times reporter Peter Goodwin.

A large, expanded-cohort pooled analysis of neoadjuvant immunotherapy for patients with resectable Stage III melanoma has reported very high rates of durable survival. The findings from the world’s biggest center of expertise in melanoma were announced at ESMO Congress 2024. The study included patients from clinical trials and real-world studies who had pure immune checkpoint inhibitor neoadjuvant therapy, or combinations including BRAF/MEK targeted therapy. After giving her talk in Barcelona, lead investigator Georgina Long, AO, PhD, MBBS, FRACP, Professor and Co-Medical Director at the Melanoma Institute Australia, University of Sydney, gave Oncology Times reporter Peter Goodwin the details.

Drug resistance can be delayed and treatment outcomes predicted in patients with ovarian cancer with the help of relatively low-cost molecular precision management techniques using liquid biopsies. These are being developed by a team at the University of California in Los Angeles (UCLA) led by Jian Yu Rao, MD, Vice Chair of Diagnostic Technology Innovation at UCLA, where he is also Chief of Cytopathology and Director of International Telepathology. At the 2024 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) held in Xiamen, China, Rao gave Oncology Times reporter Peter Goodwin details of the molecular methods he had just outlined to the conference.

The escalating danger of cardiac toxicity posed by a range of increasingly effective anti-cancer therapies is insufficiently understood, according to the head of a world center of excellence for the study of cardio-oncology in northern China. At a special session devoted to cardio-oncology held at the Chinese Society of Clinical Oncology (CSCO) 2024 Annual Meeting, the challenges of cardio-oncology were examined by a committee of experts with reference to the CSCO Clinical Practice Guide for Tumor Cardiology. Among the speakers was cardiologist Yun-Long Xia, MD, PhD, FESC, FHRS, Head of Cardiovascular Medicine at Dalian Medical University in China. Afterward, he talked about their conclusions with Oncology Times reporter Peter Goodwin.

An assessment of progress with antibody-drug conjugates (ADCs) for the treatment of HER2-dependent metastatic breast cancer was given at the 2024 Chinese Society of Clinical Oncology (CSCO) Annual Meeting. The President-Elect of the European Society for Medical Oncology (ESMO), Giuseppe Curigliano, MD, PhD, Director of the Early Drug Development for Innovative Therapies Division at the European Institute of Oncology and the University of Milano in Italy, told Oncology Times reporter Peter Goodwin about the broadening scope of ADCs in breast cancer and his reasons for encouraging ESMO and CSCO to continue to expand their co-operation.

Details of the expanding range of cell therapies beyond hematologic malignancy were reported at the 2024 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) by Oliver Dorigo, MD, PhD, Director of the Division of Gynecologic Oncology at the Stanford Women's Cancer Center in Stanford University. After his talk at CSCO, Dorigo told Oncology Times reporter Peter Goodwin about the promise cell therapies held for improving outcomes in ovarian cancer and other solid tumors, as well as the benefit of the exchange of ideas flowing between China, U.S., and other global players in this young science.

At the opening session of the Chinese Society of Clinical Oncology (CSCO) 2024 Annual Meeting, attended by nearly 30,000 cancer specialists, Oncology Times reporter Peter Goodwin asked the President of CSCO, Xu Ruihua, MD, PhD, Professor and President of Sun Yat-sen University Cancer Center in Guangzhou, China, to talk about some of the ways that progress in cancer treatments had been made more productive by co-operation between Chinese and Western centers of oncology excellence.

Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the 2024 Annual meeting of the European Society for Medical Oncology, ESMO. The Scientific Chair of the meeting, Rebecca Dent MD, Deputy Chief Executive Officer of the National Cancer Center in Singapore, told Oncology Times reporter Peter Goodwin about some of the key areas of progress covered by the meeting that she was most excited about.

A large international cohort study has found that women testing positive for the BRCA mutation who chose to breastfeed their babies after treatment for their breast cancer faced no additional risk to their cancer outcomes. OncTimesTalk correspondent Peter Goodwin talked with Eva Blondeaux, MD, Medical Oncologist in the Epidemiology Unit at the IRCCS Ospedale Policlinico San Martino, Genoa, Italy, and the author of the study, after her presentation of the new data at the ESMO 2024 Congress.

Women who chose to interrupt their endocrine therapy after their breast cancer surgery to have a baby faced no additional cancer risk, according to data from the POSITIVE study reported at the ESMO Congress 2024. In Barcelona, OncTimesTalk reporter Peter Goodwin met up with Fedro Peccatori, MD, PhD, Director of the Fertility and Procreation Unit in the Division of Gynecologic Oncology at the European Institute of Oncology, Milan, Italy, after he reported his group’s findings. “Breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy: Results from the POSITIVE trial,” Peccatori noted.

HPV vaccination for girls and boys in the United States has led to a real-world reduction of oral head and neck cancers in men, as well as the already documented prevention of cervical cancers in women, even though uptake of the vaccine in the U.S. has been suboptimal. This is according to findings from a retrospective analysis of HPV-associated cancer incidence, reported at the 2024 ASCO Annual Meeting. At the Chicago meeting, OncTimesTalk reporter Peter Goodwin met up with the lead author of the research, Jefferson DeKloe, BSc, from the Department of Otolaryngology at Thomas Jefferson University in Philadelphia.

Although co-medication with proton pump inhibitors (PPI) is not advised for patients being treated with dasatanib for their chronic myeloid leukemia (CML), confirmation that this recommendation is often overlooked has been reported in a study led by Torsten Dahlén, a PhD student at the Karolinska Institutet in Stockholm, Sweden. Furthermore, the study found a higher than previously reported negative interaction of PPI comedication on crystalline dasatinib bioavailability that may compromise clinical efficacy and risk CML disease progression. The latest findings from the study were reported in a poster session at the 2024 ASCO Annual Meeting where Oncology Times reporter Peter Goodwin met up with Olof Harlin, PhD, of Xspray Pharma, based in Solna, near Stockholm, Sweden.

Patients who had immune-related adverse events had better responses and lived longer than those who didn't. This was a real-world observational study of patients with recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint inhibitor monotherapy, reported at the 2024 ASCO Annual Meeting. OncTimesTalk reporter Peter Goodwin caught up with the lead study author Chiara Gottardi, MD, who specializes in head and neck cancer in the Department of Surgery, Oncology, and Gastroenterology in the Istituto Oncologico Veneto at the University of Padova in Italy.

A mathematical model using data from routine diagnostic samples has been found to accurately predict individual patient responses to the main candidate first-line treatments for acute myeloid leukemia. Findings from a validation study in independent patient cohorts led by researchers from the Barts Cancer Institute at the Queen Mary University of London were reported at a poster session of the 2024 ASCO Annual Meeting. Oncology Times correspondent Peter Goodwin attended the session and talked with the second author of the study, Weronika E. Borek PhD, a Bioinformatics Technical Lead at Kinomica Limited in London.

Not only can palliative care be delivered effectively by telehealth to patients with advanced non-small cell lung cancer, it's also as effective as face-to-face delivery by specialist clinicians, according to a study reported at the 2024 ASCO Annual Meeting. In addition, telehealth turned out to be more popular. For the Oncology Times podcast, OncTimesTalk, correspondent Peter Goodwin spoke with Joseph A. Greer, PhD, lead author of the study and Co-Director of the Cancer Outcomes Research and Education Program at Massachusetts General Hospital and Harvard Medical School.

A combination of two checkpoint inhibitors used as neoadjuvant therapy for macroscopic, resectable Stage III melanoma brought a highly statistically significant improvement over the standard of care: surgery followed by checkpoint inhibition (therapeutic lymph node dissection followed by adjuvant therapy with nivolumab, pembrolizumab or, in BRAFmut melanoma, dabrafenib + trametinib). This research was reported from the ASCO 2024 Annual Meeting and highlighted the NADINA trial from the Netherlands. After his session at ASCO, the lead author of NADINA, Christian U. Blank, MD, PhD, from the Netherlands Cancer Institute and Antoni van Leeuwenhook Hospital, Amsterdam, the Netherlands, met up with Oncology Times reporter Peter Goodwin to discuss the findings.

When the mucin-1 (MUC-1) vaccine tecemotide was added to standard-of-care neoadjuvant systemic therapy, investigators in Austria found improved long-term outcomes in women with early breast cancer. Individuals vaccinated with tecemotide had markedly longer distant recurrence-free and overall survival. This was in the randomized prospective ABCSG-34 trial presented at the 2024 ASCO Annual Meeting. Oncology Times reporter Peter Goodwin met up in Chicago with the lead study author, Christian F. Singer MD, a gynecologist specializing in breast cancer at the Department of Obstetrics and Gynecology and the Comprehensive Cancer Center of the Medical University of Vienna, in Vienna, Austria.

The CARACO prospective, multi-institutional, Phase III trial, among patients with newly diagnosed advanced epithelial ovarian cancer, found that lymphadenectomy should be omitted in patients with clinically negative lymph nodes, as well as those undergoing neoadjuvant chemotherapy and interval complete surgery. This finding from the University of Nantes was reported at the 2024 ASCO Annual Meeting. The researchers noted this surgical de-escalation allows significant reduction of serious post-operative morbidity After the session, Oncology Times correspondent Peter Goodwin learned about more study details from Jean-Marc Classe, MD, PhD, Professor of Surgery in the Department of Surgical Oncology in the Institut de Cancérologie de l'Ouest and Nantes University in Western France.

Primary results from ASC4FIRST trial, the first study in chronic myeloid leukemia comparing current standard-of-care frontline tyrosine kinase inhibitors with the novel agent asciminib in newly diagnosed patients, were reported at the 2024 ASCO Annual Meeting. First author Timothy Hughes MD, Consultant Hematologist with the Royal Adelaide Hospital, the South Australian Health and Medical Research Institute, and the University of Adelaide in Australia, reported higher efficacy in terms of major molecular responses and lower toxicity with asciminib. After his talk in Chicago, he met up with Oncology Times reporter, Peter Goodwin.

Data from the DESTINY Breast06 trial using the antibody-drug conjugate trastuzumab deruxtecan to treat patients with estrogen receptor positive (HR+), human epidermal growth factor receptor-low (HER2-low), and HER2-ultralow breast cancer after endocrine therapy, show longer progression-free survival in comparison with standard chemotherapy. After announcing the results at the 2024 ASCO Annual Meeting, first author Giuseppe Curigliano, MD, PhD, Director of Early Drug Development for the Innovative Therapies Division of the European Institute of Oncology, discussed the findings with Oncology Times correspondent Peter Goodwin

Treatment with perioperative chemotherapy, with chemotherapy before and after surgery, brought superior outcomes for patients with locally advanced esophageal adenocarcinoma, in research reported to the 2024 ASCO Annual Meeting. Lead author Jens Höppner FAChirg, FACS, MD, Director of the Department of Surgery in the University Medical Center at the University of Bielefeld in Germany, spoke with Oncology Times reporter Peter Goodwin about his group’s comparison of neoadjuvant therapy using the CROSS (41.4 Gy plus carboplatin/paclitaxel) regimen followed by surgery, with the use of an alternative protocol: perioperative FLOT (5-FU/ leucovorin/oxaliplatin/docetaxel) and surgery, in which chemotherapy is given both before and after curative surgery.

Brandt's field operation manager says a huge team effort to put together the site at this year's Fieldays has paid off - Brandt won the best outdoor site over 400m2.See omnystudio.com/listener for privacy information.

Jamie Mackay talks to David Seymour, Nicola Willis, Sir David Fagan, Bruce Weir, Peter Goodwin, Kieran McAnulty, Nadine Tunley, Mark de Lautour, and Gerard Vaughan.See omnystudio.com/listener for privacy information.

When the immune checkpoint inhibitor durvalumab was added to standard-of-care chemoradiation treatment for patients with limited-stage small-cell lung cancer, it brought a “statistically significant and clinically meaningful” improvement in overall and progression-free survival, compared to adding placebo. This was in data from the ADRIATIC study reported in the Plenary Session at the 2024 ASCO Annual Meeting in Chicago. Peter Goodwin was there for Oncology Times, where he talked with the lead author of the new research, David Spigel, MD, Chief Scientific Officer at Sarah Cannon Research Institute in Nashville, TN.

An improvement over standard care in both efficacy and safety of a new combination regimen for treating Hodgkin lymphoma was discussed at the 2024 ASCO Annual Meeting in Chicago. The six-drug BrECADD regimen was compared with the high-achieving German-originated BEACOPP chemotherapy that has been widely adopted as standard of care. During the conference, Oncology Times reporter Peter Goodwin met up with Peter Borchmann, MD, PhD, the lead author of the new research and Chair of the German Hodgkin Study Group at the University Hospital of Cologne in Germany.

New data from the Phase III LAURA study, reported in Chicago at the ASCO 2024 Annual Meeting Plenary Session, suggest that the tyrosine kinase inhibitor osimertinib could become standard of care for treating patients whose unresectable locally advanced lung cancers test positive for mutated epidermal growth factor receptor (EGFR) and have no progression after definitive chemoradiotherapy. In Chicago, Oncology Times reporter Peter Goodwin met up with lead author of the LAURA study, Suresh S. Ramalingam MD, Executive Director of the Winship Cancer Institute at Emory University School of Medicine in Atlanta.

A combination of a new mRNA vaccine used together with a programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor to treat patients with lung cancer was markedly less toxic than a combination of the same vaccine with chemotherapy. However, it was apparently just effective. This is according to findings from a study reported to the 2024 AACR Annual Meeting. The randomized study, led by the researchers at the Moffitt Cancer Center, looked at a combination of the mRNA-based active cancer vaccine BI1361849 combined with the anti-PD-L1 checkpoint inhibitor durvalumab with or without the anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) checkpoint inhibitor tremelimumab immunotherapy. After announcing the findings at the AACR, presenting author Dung-Tsa Chen, PhD, Senior Member in the Department of Biostatistics & Informatics, Special Clinical Trial Design, and Data Analysis at the Moffitt Cancer Center, called in to discuss the new data with OncTimesTalk correspondent Peter Goodwin.

The 2024 AACR Annual Meeting heard that an “efficacy signal” was detected in an international Phase I study of a new radiosensitizer, tested as adjunctive therapy (combined with standard radiation plus temozolomide) in patients with recurrent glioblastoma. After reporting his group's early findings of AZD1390, an inhibitor of ataxia telangiectasia mutated (ATM) kinase studied in 115 patients with recurrent or newly diagnosed glioblastoma, first author Jonathan T. Yang MD, PhD, previously from the Memorial Sloan Kettering Cancer Center and now at UW Medicine, stepped into the Oncology Times studio at the AACR conference to tell OncTimesTalk's reporter Peter Goodwin about the safety of this new agent and the clinical value it could bring in glioblastoma.

A new blood test that uses artificial intelligence to analyze circulating molecular markers for the earliest signs of ovarian and other cancers has been reported by researchers. At the AACR 2024 Annual Meeting in San Diego, Victor Velculescu, MD, PhD, Co-Director of the Cancer Genetics & Epigenetics Program at Johns Hopkins Kimmel Cancer Center, reported his group's validation of the test that assesses the pattern of circulating fragments of tumor DNA, known as fragmentomes. After discussing the findings at an AACR press briefing, Velculescu joined Peter Goodwin in the OncTimesTalk podcast studio to discuss the clinical implications.

Findings from a new study support a body of evidence showing that physical exercise can bring benefits to patients with advanced prostate cancer. Data from an intervention study reported at the AACR Annual Meeting 2024 are consistent with mounting epidemiological evidence showing that regular physical exercise can help patients with advanced or metastatic prostate cancer “deter” death, slow disease progression, and improve quality of life. Stacey A. Kenfield, ScD, Professor of Urology and the Helen Diller Family Chair in Population Science for Urologic Cancer at the University of California San Francisco (UCSF), reported early data from the INTERVAL-GAP4 trial. Together with her colleague, June Chan, ScD, Professor of Epidemiology & Biostatistics in Urology at UCSF, she called into the Oncology Times studio at the San Diego conference to tell OncTimesTalk anchor, Peter Goodwin, about the newest findings and recommendations for using physical exercise as a form of therapy for patients with prostate and other cancers.

An early study using selective inhibition of the Poly (ADP-ribose) polymerase (PARP) has provided evidence it could bring greater cancer control with less toxicity than the well-proven non-selective PARP 1 and PARP 2 inhibitors already in use for treating a number of tumor types. At the AACR Annual Meeting 2024, Timothy Yap, PhD, MD, MBBS, Vice President and Head of Clinical Development in the Therapeutics Discovery Division at the University of Texas MD Anderson Cancer Center, reported early data from the PETRA study looking at the selective PARP 1 inhibitor saruparib under investigation as a potentially safer, yet more effective, alternative to the non-selective PARP 1/PARP 2 inhibitors currently licensed for prostate, ovarian, breast, and other cancers. After announcing the new research findings at a clinical session at AACR, he met up with Oncology Times reporter Peter Goodwin to discuss the new data and their clinical potential.

Double checkpoint blockade using a single bispecific agent could become the new standard for treating advanced gastric cancer regardless of PD-L1 status, according to research reported at the AACR Annual Meeting 2024. The investigational bispecific antibody drug cadonilimab (used with chemotherapy) significantly extended life and delayed disease progression among patients with HER2-negative advanced or metastatic gastric or gastroesophageal junction cancers reported from Chinese investigators. The first author of the report, Jiafu Ji, MD, PhD, DrPH, FACS, FRCS, Fellow of the Chinese Academy of Medical Science, as well as Professor and Chief of the Gastrointestinal Cancer Center at Peking University Cancer Hospital and the Beijing Institute for Cancer Research in China, called into the Oncology Times office at AACR after his talk to discuss his team's findings with Peter Goodwin, an OncTimesTalk correspondent.

An opportunity to detect pancreatic cancer at stages where early intervention can greatly extend life and even make cure possible seems to be on offer, according to findings from a study of a new liquid biopsy method based on so-called exosomes: subcellular molecules shed into the circulation by cancer cells. At the AACR Annual Meeting 2024 in San Diego, Peter Goodwin talked with Ajay Goel, PhD, AGAF, senior author of the study and Chair of the Molecular Diagnostics and Experimental Therapeutics in the Beckman Research Institute at City of Hope in Los Angeles.

Designed with the help of artificial intelligence to recognize multiple genetic features of each patient's tumor, a small clinical trial of a personalized therapeutic vaccine has shown durable tumor-specific immune responses in patients with surgically resected HPV-negative head and neck squamous cell cancer. The vaccine also prevented relapse in some patients. At the AACR Annual Meeting 2024, Olivier Lantz, MD, PhD, Head of the Clinical Immunology Laboratory at the Institut Curie Hospital in Paris, reported data using a “neoantigen-based vaccine” specifically designed to recognize multiple genetic features unique to each patient's tumor. During the conference, Lantz called into the OncTimesTalk studio to tell Peter Goodwin about the clinical options that could develop from such highly personalized vaccines.

The Pediatric Physical Therapy Podcast March, 2024 Edition: AN INTERVIEW WITH: Eilish M Byrne PT, DSc, PCS, CNT, Assistant Professor, Camino Hospital and Stanford Children's Hospital, California, Visiting Professor University of St Augustine, San Marcos, California. In conversation with Peter Goodwin, Editor, The Pediatric Physical Therapy Podcast (March, 2024 Edition) DESCRIPTION: Dr. Byrne discusses the research her ream has published in Pediatric Physical Therapy, Volume 36, Number 2, 2024 on: “Introducing the i-Rainbow- An evidence-based, parent-friendly care pathway designed for even the most critically ill infant in the Neonatal Intensive Care setting.” AUTHORS: Eilish M. Byrne, Katherine Hunt and Melissa Scala SUMMARY: This study investigated the feasibility and effectiveness of a novel, evidence-based developmental care pathway to be used by healthcare providers and parents in the neonatal intensive care setting. PURPOSE: This study investigated the feasibility and effectiveness of a novel, evidence-based developmental care pathway to be used by healthcare providers and parents in the neonatal intensive care setting (NICU). The iRainbow is based on current evidence and responds to individual infant health status. It is not base on infant age. METHODS: After development and implementation of the iRainbow, pre-and post- implementation nurse and parent survey data were collected, and pre- and post-developmental care rates were compared. RESULTS: After iRainbow implementation, disagreement among providers on appropriate developmental care interventions significantly decreased, total minutes of daily developmental care and swaddled holding increased significantly, and parents reported that they would recommend the tool. CONCLUSION: The iRainbow is a unique, parent-friendly, infant-based tool that guides sensory interventions in the NICU by staging infants based on cardiorespiratory status and physiologic maturity, not age. The iRainbow improved the delivery of developmental care activities in our unit and was well received by parents and nurses. KEYWORDS: iRainbow, Neonatal Intensive Care Unit, Neonatal Therapy, Developmental Care, Neonatal Sensory Interventions, Neonatal Care Path, Family Education WHAT THIS EVIDENCE ADDS: Current evidence: There are many studies and programs demonstrating the benefits of providing evidence-based developmental interventions for both neonates and caregivers.1-4 Gap in the evidence: There is less agreement regarding the safety and timing of developmental interventions7-9, and what does exist tends to rely on gestational age, while recommending performing activities per infant tolerance.5,6 However, this approach can be problematic because preterm infants progress at variable rates, and infant tolerance is not objectively defined. How does this study fill this gap? This study provides objective clinical criteria to define neonate tolerance for intervention guided by the cardiorespiratory stability of the infant, and in later stages, behavior cues of the infant, not gestational age. Implication of all the evidence: Optimal timing of and tolerance to evidence-based developmental interventions in the NICU is still being described. Relying solely on gestational ages may not be ideal for many infants. The iRainbow serves as a valuable tool to objectively identify an infant's readiness to participate in a developmental care program.

On this episode, Peter Goodwin shares how his company offers exceptional customer service that honors the Lord. Peter Goodwin is a former Alaskan hunting/adventure guide who now owns and is CEO of Groove Life, a $50 million active/outdoor brand selling silicone rings, belts, wallets, and other everyday accessories. www.GrooveLife.com Christianity in Business is the show that helps Christian business leaders to integrate biblical values into business. | Entrepreneurship | Marketing | Nonprofit | Church | Author | Startups | Marketplace | Ministry | Business as Mission | Faith and Work | Faith | Success | Leadership | www.ChristianityInBusiness.com   

On this episode, Peter Goodwin shares how his company offers exceptional customer service that honors the Lord. Peter Goodwin is a former Alaskan hunting/adventure guide who now owns and is CEO of Groove Life, a $50 million active/outdoor brand selling silicone rings, belts, wallets, and other everyday accessories. www.GrooveLife.com Christianity in Business is the show that helps Christian business leaders to integrate biblical values into business. | Entrepreneurship | Marketing | Nonprofit | Church | Author | Startups | Marketplace | Ministry | Business as Mission | Faith and Work | Faith | Success | Leadership | www.ChristianityInBusiness.com   

Peter Goodwin, CEO and Founder of Groove Life, sits down to discuss how his “side project” ended up evolving into his second career as an entrepreneur, as well as how their product line has expanded from their original silicone wedding bands. Goodwin and host of #ThePlaybook, David Meltzer, share their thoughts on a wide range of subjects including the role that faith plays, why you should promote innovation and treat failure as “the ultimate tutor” within your business, and the biggest mistake that entrepreneurs make when transitioning careers. Goodwin also chats about his aspirations for the future of the brand. Tweet me your takeaway from today's episode @davidmeltzer  Email Me! david@dmeltzer.com Sign up for my Free Weekly Training https://free.dmeltzer.com/friday-training-1 Text Me! (949) 298-2905 Learn more about your ad choices. Visit podcastchoices.com/adchoices